Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03130270 | Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma | unknown | Phase 2 | 29 | Guilin Medical University, ChinaOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03525782 | Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC | unknown | Phase 1 / Phase 2 | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03520257 | The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | unknown | Phase 2 | 50 | Guangxi Medical UniversityOTHER | 0 | May 9, 2018 | clinicaltrials |
| NCT03511703 | The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | unknown | Phase 2 | 40 | Guangxi Medical UniversityOTHER | 0 | Apr 30, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02134990 | Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer | unknown | Phase 2 | 20 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT02879214 | Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer(Side) | unknown | Phase 2 | 50 | Sichuan Provincial People's HospitalOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01890096 | A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer | unknown | Phase 2 | 174 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT03497702 | Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer(NeoChAI) | unknown | Phase 2 | 114 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 13, 2018 | clinicaltrials |
| NCT03257891 | Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines(CabACC) | unknown | Phase 2 | 25 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation(Geber) | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 3, 2018 | clinicaltrials |
| NCT03486509 | Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma | unknown | Phase 2 | 2 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 3, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT03460275 | Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03461185 | Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 100 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03446911 | Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery | unknown | Phase 1 / Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT03444025 | Neoadjuvant Goserelin for Triple Negative Breast Cancer(NeoGONT) | unknown | Phase 2 | 180 | Kasr El Aini HospitalOTHER | 0 | Feb 23, 2018 | clinicaltrials |
| NCT03424759 | Uncommon EGFR AZD9291 | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT03424291 | A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 6, 2018 | clinicaltrials |
| NCT03416231 | Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 2 | 20 | Affiliated Hospital of North Sichuan Medical CollegeOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02734524 | A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 2 | 104 | Southwest Hospital, ChinaOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02852083 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC(ModuLung) | unknown | Phase 2 | 86 | University Hospital RegensburgOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02978547 | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma(Metformin 001) | unknown | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03196388 | Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer(ENZART) | unknown | Phase 2 | 70 | Fundación Canaria Instituto de Investigación Sanitaria de CanariasOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03127319 | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | unknown | Phase 2 | 40 | Affiliated Hospital of Hebei UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03399669 | The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation | unknown | Phase 2 | 100 | Samsung Medical CenterOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT03387943 | PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 3, 2018 | clinicaltrials |
| NCT02072044 | Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy | unknown | Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02590133 | A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC | unknown | Phase 2 | 328 | Yun-fei XiaOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT03209206 | The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence | unknown | Phase 2 | 84 | Seoul National University HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT03344068 | Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 408 | Sun Yat-sen UniversityOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02410369 | Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer | unknown | Phase 2 | 60 | Tokyo UniversityOTHER | 1 | Dec 21, 2017 | clinicaltrials |
| NCT02311205 | Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)(COTSOM) | unknown | Phase 2 | 55 | Asan Medical CenterOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03356912 | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | unknown | Phase 2 | 220 | Consorzio OncotechOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT03135977 | Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy | unknown | Phase 2 | 36 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT03356444 | Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 140 | West China HospitalOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT03356587 | A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy | unknown | Phase 2 | 32 | Seoul National University HospitalOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03348098 | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT02215447 | A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas(NABNEC) | unknown | Phase 2 | 4 | Barwon HealthOTHER_GOV | 1 | Nov 22, 2017 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03341494 | EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide | unknown | Phase 2 | 128 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03337841 | Pembrolizumab as Neoadjuvant Treatment in HCC | unknown | Phase 2 | 50 | Kindai UniversityOTHER | 0 | Nov 9, 2017 | clinicaltrials |
| NCT01217034 | Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib(TACTICS) | unknown | Phase 2 | 228 | Kindai UniversityOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02862015 | Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients(Oncothermia) | unknown | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT03290820 | Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients | unknown | Phase 2 | 184 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02499614 | Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)(METROS) | unknown | Phase 2 | 80 | Fondazione Ricerca TraslazionaleOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT01348256 | Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma | unknown | Phase 2 | 58 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
Data updated 24 days agoSource updated May 16, 2018source: clinicaltrials